Previous 10 | Next 10 |
Shares of MediciNova Inc. (NASDAQ:MNOV) traded today at $3.84, breaking its 52-week low. Approximately 3.3 million shares have changed hands today, as compared to an average 30-day volume of 298,000 shares. MediciNova Inc. (NASDAQ:MNOV) has potential upside of 38.3% based on a current pr...
10 Hot Biotech Penny Stocks For Your Watchlist Next Month Biotech penny stocks are heating up right now. While this began a few months after the onset of Covid, since then, penny stocks in the biotech sector have continued to make headway. One thing to keep in mind is that biotech...
New Concept Energy (GBR) -20%.MicroVision (MVIS) -9% after announces $140M at-the-market equity facilityPEDEVCO (PED) -8%.Focus Financial Partners (FOCS) -8% after prices secondary stock offering at $50.30.Moxian (MOXC) -8%.Anavex Life Sciences (AVXL) -7% on laun...
Are These Penny Stocks on Reddit Worth Watching? Finding penny stocks on Reddit has become a popular choice for those looking to stay informed. While Reddit should not be the only place you find penny stocks to buy , it can be a great tool for seeing which stocks are trending. Over ...
Gainers: Virpax Pharmaceuticals (VRPX) +16%, Anavex Life Sciences AVXL +15%, MediciNova MNOV +14%, Aytu Biopharma (AYTU) +14%, Applied Molecular Transport (AMTI) +8%.Losers: Aptevo Therapeutics (APVO) -18%, Intec Pharma (NTEC) -16%, Conformis ...
Merger news and drug development moved some stocks in Monday's pre-market action. Raven (RAVN) and Rafael Holdings (RFL) advanced on merger deals. Meanwhile, MediciNova (MNOV) and Theravance Bio (TBPH) moved in opposite directions on the release of new clinical trial data.The return of travel...
MediciNova (MNOV) +52% on positive MN-166 data.Raven Industries (RAVN) +50% on being acquired by CNHI for $58.0 per share.Torchlight Energy Resources (TRCH) +39% after update on proposed business combination timing and date for preferred dividend.Hennessy Capital Investment Cor...
MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment ...
LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibu...
LA JOLLA, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive...
News, Short Squeeze, Breakout and More Instantly...
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market o...
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S....
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D....